Desafíos en la adherencia a STRIDE-II: perspectivas de gastroenterólogos y pacientes con enfermedad inflamatoria intestinal

Simple item page
dc.coverageDOI: 10.1016/j.gastrohep.2025.502440
dc.creatorCarvajal, Francisca
dc.creatorHerrera, Karin
dc.creatorNúñez, Paulina
dc.creatorFlores, Lilian
dc.creatorCórdova, Andrea
dc.creatorPizarro, Gonzalo
dc.creatorSan Martín, Pamela
dc.creatorQuera, Rodrigo
dc.date2025
dc.date.accessioned2026-01-05T21:15:53Z
dc.date.available2026-01-05T21:15:53Z
dc.description<p>Introduction The treatment aims to achieve symptomatic remission, normalization of biomarkers such a fecal calprotectin, and endoscopic remission. Therefore, early recognition of inflammatory activity and timely therapeutic intervention are essential to improve the morbidity and mortality. Objective Evaluate the adherence among gastroenterologists and the patients compliance with medical recommendations in the Inflammatory Bowel Disease Program at Clínica Universidad de los Andes Patients and methods A retrospective study that included patients presenting with a flare confirmed by colonoscopy. Three follow-up stages were defined: Short-Term Control: symptomatic remission at 3 months, Medium-Term Control: remission of fecal calprotectin as a biomarker (&lt; 250 μg/g) between 4 and 6 months, and Long-Term Control: endoscopic remission between 6 and 9 months. Results A total of 104 patients were evaluated, 64% of the cohort were females and a median age of 41 years. Among them, 81% had Crohn's disease, with an inflammatory phenotype in 87% and colonic localization in 39%. The remaining 19% had ulcerative colitis with left-sided involvement in 50%. Ninety percent of the patients attended short term control with a symptomatic remission in 72%. Eighty-two percent attended medium term control, resulting in biomarker remission for 83% of them. Seventy seven percent attended long term control, achieving endoscopic remission in 59% of the cases. Conclusion The results indicate that our program achieves a physician adherence of over 90% to STRIDE-II, with patient's adherence to pharmacological therapy and follow up above 70%. Although these are high percentages, they are subject to improvement.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/5e43cf30-9f61-4dc0-b57e-3b303a66bd96
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/66776
dc.languagespa
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.sourcevol.48 (2025) nr.9 p.502440
dc.subjectAdherence
dc.subjectCrohn's disease
dc.subjectInflammatory bowel disease
dc.subjectTreat to target
dc.subjectUlcerative colitis
dc.titleDesafíos en la adherencia a STRIDE-II: perspectivas de gastroenterólogos y pacientes con enfermedad inflamatoria intestinalspa
dc.titleChallenges in adherence to STRIDE-II: Perspectives from gastroenterologists and patients with inflammatory bowel diseaseeng
dc.titleDesafíos en la adherencia a STRIDE-II: perspectivas de gastroenterólogos y pacientes con enfermedad inflamatoria intestinalspa
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
Pure-CRIS